1. Home
  2. TSLX vs EVO Comparison

TSLX vs EVO Comparison

Compare TSLX & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TSLX
  • EVO
  • Stock Information
  • Founded
  • TSLX 2010
  • EVO 1993
  • Country
  • TSLX United States
  • EVO Germany
  • Employees
  • TSLX N/A
  • EVO N/A
  • Industry
  • TSLX Investment Managers
  • EVO Biotechnology: Pharmaceutical Preparations
  • Sector
  • TSLX Finance
  • EVO Health Care
  • Exchange
  • TSLX Nasdaq
  • EVO Nasdaq
  • Market Cap
  • TSLX 2.1B
  • EVO 1.5B
  • IPO Year
  • TSLX 2014
  • EVO 2021
  • Fundamental
  • Price
  • TSLX $24.14
  • EVO $4.21
  • Analyst Decision
  • TSLX Strong Buy
  • EVO Buy
  • Analyst Count
  • TSLX 8
  • EVO 2
  • Target Price
  • TSLX $22.69
  • EVO $5.90
  • AVG Volume (30 Days)
  • TSLX 607.2K
  • EVO 119.8K
  • Earning Date
  • TSLX 07-30-2025
  • EVO 08-13-2025
  • Dividend Yield
  • TSLX 8.63%
  • EVO N/A
  • EPS Growth
  • TSLX N/A
  • EVO N/A
  • EPS
  • TSLX 1.89
  • EVO N/A
  • Revenue
  • TSLX $481,092,000.00
  • EVO $851,944,444.00
  • Revenue This Year
  • TSLX N/A
  • EVO $10.08
  • Revenue Next Year
  • TSLX N/A
  • EVO $10.99
  • P/E Ratio
  • TSLX $12.77
  • EVO N/A
  • Revenue Growth
  • TSLX 4.73
  • EVO 1.50
  • 52 Week Low
  • TSLX $18.58
  • EVO $2.84
  • 52 Week High
  • TSLX $24.42
  • EVO $5.64
  • Technical
  • Relative Strength Index (RSI)
  • TSLX 64.03
  • EVO 53.18
  • Support Level
  • TSLX $23.75
  • EVO $4.15
  • Resistance Level
  • TSLX $24.42
  • EVO $4.26
  • Average True Range (ATR)
  • TSLX 0.36
  • EVO 0.11
  • MACD
  • TSLX 0.04
  • EVO 0.01
  • Stochastic Oscillator
  • TSLX 84.62
  • EVO 77.42

About TSLX Sixth Street Specialty Lending Inc.

Sixth Street Specialty Lending Inc is a specialty finance company focused on providing flexible, fully committed financing solutions to middle market companies located in the United States of America. It partners with companies across a variety of industries and excel at providing creative solutions to companies with complex business models that may have limited access to capital. The company seeks to generate current income in U.S.-domiciled middle-market companies through direct originations of senior secured loans and, to a lesser extent, originations of mezzanine and unsecured loans and investments in corporate bonds and equity securities.

About EVO Evotec SE

Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

Share on Social Networks: